Skip to content
Screener

Twist Bioscience Corporation TWST Reportable Segment — Net loss, basic and diluted

Similar metrics at other companies

Amgen logo
AMGNReportable Segment — Net income for basic and diluted EPS
$2.38B+65.9%
Veradermics logo
MANEReportable Segment — Net loss
-$27.23M-120%
Zscaler logo
ZSReportable Segment — Net loss
-$13.88M-237%
Biohaven logo
BHVNReportable Segment — Net loss
-$130.53M+41.1%
Bicara Therapeutics logo
BCAXReportable Segment — Net loss
-$56.21M-52.6%
YSS
YSSReportable Segment — Net loss
-$114.84M-879%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(In thousands, except per share data)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Other income (expense), net[1]175(394)646(487)
Loss before income taxes$(43,978)$(39,153)$(74,232)$(70,651)
Income tax expense(43)(175)(296)(271)
Net loss$(44,021)$(39,328)$(74,528)$(70,922)
Other comprehensive loss:
Change in unrealized gain (loss) on investments$(85)$30$(67)$97
Foreign currency translation adjustment17(25)5543
Comprehensive loss$(44,089)$(39,323)$(74,540)$(70,782)

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's reportable segment — net loss, basic and diluted?
Twist Bioscience Corporation (TWST) reported reportable segment — net loss, basic and diluted of -$44.02M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — net loss, basic and diluted changed year-over-year?
Twist Bioscience Corporation's reportable segment — net loss, basic and diluted decreased by 11.9% year-over-year, from -$39.33M to -$44.02M.
What does reportable segment — net loss, basic and diluted mean?
This represents the final bottom-line financial result for the reportable segment after all operating expenses, taxes, and non-operating items have been accounted for. A net loss indicates that the segment's costs and expenses exceeded its revenues during the period. Tracking this is critical for assessing the segment's path toward self-sustainability and profitability.

Ask your AI about Twist Bioscience Corporation's reportable segment — net loss, basic and diluted.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude